Catalyst Event
RemeGen Co Ltd (9995) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
5/29/2026, 12:00:00 AM
RemeGen's shares were included in the MSCI China Index, effective after market close on May 29, 2026. Analysts estimate this will drive institutional demand with a price impact of at least 5%, estimated.
Korean Translation
2026년 5월 29일 장 마감 후 MSCI 중국 지수에 편입됨. 전문가들은 지수 편입에 따른 기관 수요 유입으로 5% 이상의 주가 영향이 있을 것으로 예상함.
Related Recent Events
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
United Laboratories International Holdings Ltd (3933) · Other
The Annual General Meeting is scheduled for June 23, 2026, to vote on financial statements and a potential 20% share issuance mandate which could dilute existing shareholdings; high importance due to potential dilution, scheduled.
6/23/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
6/19/2026, 12:00:00 AM